Fact CheckerSign in

NCT07687914Not yet recruitingPhase 2

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase II Clinical Study of IMM2510 for Injection Combined With IMM27M for Injection in Advanced Hepatocellular Carcinoma

Source: ClinicalTrials.gov · Last updated 7 Jul 2026

Brief summary (registry, in English)

This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
50 (estimated)
First submitted
17 Jun 2026
Start date
23 Jul 2026
Primary completion date
23 Jul 2027
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT number
NCT07687914

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 50
  • From 23 Jul 2026 to the primary completion date, 23 Jul 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of other malignancy within the past 5 years with exceptions.
    • Systemic chemotherapy was administered within 4 weeks prior to the first administration.
    • Activated symptomatic brain metastases and leptomeningeal disease.
    • History of hepatic encephalopathy disease in past 12 months.
    • Participants with symptoms and/or clinical signs and/or uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.

Who the study is looking for

  • Participant has provided informed consent prior to initiation of any study specific activities/procedures.
  • Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent.
  • Histologically or cytologically confirmed for HCC
  • Eastern Cooperative Oncology Group (ECOG) 0 to 1.
  • Adequate organ function as defined in protocol.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.